Suggested Topics within your search.
Showing 161 - 180 results of 503 for search '"Johns Hopkins University"', query time: 0.07s Refine Results
  1. 161
  2. 162
  3. 163

    Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era by Ayotola Fatola, Michael D. Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan Woods, Ara Metjian, Yara A. Park, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K. Liles, Susan Eubanks, Frank Akwaa, Todd Clover, Lisa Baumann Kreuziger, J. Evan Sadler, Meera Sridharan, Ronald S. Go, Keith R. McCrae, Harsh Vardhan Upreti, Ming Y. Lim, Nicole K. Kocher, Radhika Gangaraju, X. Long Zheng, Jay S. Raval, Camila Masias, Spero R. Cataland, Marshall Mazepa, Shruti Chaturvedi

    Published 2025-01-01
    “…Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). …”
    Get full text
    Article
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180